Up-regulated Expression of Two-pore Domain K Channels, KCNK1 and KCNK2, is Involved in the Proliferation and Migration of Pulmonary Arterial Smooth Muscle Cells in Pulmonary Arterial Hypertension

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Feb 27

PMID 38410243

Authors

Natsumi Shima

Aya Yamamura

Moe Fujiwara

Taiki Amano

Kazuyuki Matsumoto

Taiga Sekine

Haruka Okano

Rubii Kondo

Yoshiaki Suzuki

Hisao Yamamura

Affiliations

Soon will be listed here.

Abstract

Background: Pulmonary arterial hypertension (PAH) is a severe and rare disease in the cardiopulmonary system. Its pathogenesis involves vascular remodeling of the pulmonary artery, which results in progressive increases in pulmonary arterial pressure. Chronically increased pulmonary arterial pressure causes right ventricular hypertrophy and subsequent right heart failure. Pulmonary vascular remodeling is attributed to the excessive proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs), which are induced by enhanced Ca signaling following the up-/down-regulation of ion channel expression.

Objectives: In the present study, the functional expression of two-pore domain potassium KCNK channels was investigated in PASMCs from idiopathic PAH (IPAH) patients and experimental pulmonary hypertensive (PH) animals.

Results: In IPAH-PASMCs, the expression of KCNK1/TWIK1 and KCNK2/TREK1 channels was up-regulated, whereas that of KCNK3/TASK1 and KCNK6/TWIK2 channels was down-regulated. The similar up-regulated expression of KCNK1 and KCNK2 channels was observed in the pulmonary arterial smooth muscles of monocrotaline-induced PH rats, Sugen 5416/hypoxia-induced PH rats, and hypoxia-induced PH mice. The facilitated proliferation of IPAH-PASMCs was suppressed by the KCNK channel blockers, quinine and tetrapentylammonium. The migration of IPAH-PASMCs was also suppressed by these channel blockers. Furthermore, increases in the proliferation and migration were inhibited by the siRNA knockdown of KCNK1 or KCNK2 channels. The siRNA knockdown also caused membrane depolarization and subsequent decrease in cytosolic [Ca]. The phosphorylated level of c-Jun N-terminal kinase (JNK) was elevated in IPAH-PASMCs compared to normal-PASMCs. The increased phosphorylation was significantly reduced by the siRNA knockdown of KCNK1 or KCNK2 channels.

Conclusion: Collectively, these findings indicate that the up-regulated expression of KCNK1 and KCNK2 channels facilitates the proliferation and migration of PASMCs via enhanced Ca signaling and JNK signaling pathway, which is associated with vascular remodeling in PAH.

Citing Articles

Highly Selective Artificial K Transporters Reverse Liver Fibrosis In Vivo.

Zhang Q, Liang Q, Wang G, Xie X, Cao Y, Sheng N JACS Au. 2024; 4(10):3869-3883.

PMID: 39483224 PMC: 11522913. DOI: 10.1021/jacsau.4c00521.

Overexpressed KCNK1 regulates potassium channels affecting molecular mechanisms and biological pathways in bladder cancer.

Zhang W, Chen X, Wei Y, Wang X, Chen X, Chi B Eur J Med Res. 2024; 29(1):257.

PMID: 38689322 PMC: 11059691. DOI: 10.1186/s40001-024-01844-1.

References

Miyaki R, Yamamura A, Kawade A, Fujiwara M, Kondo R, Suzuki Y . SKF96365 activates calcium-sensing receptors in pulmonary arterial smooth muscle cells. Biochem Biophys Res Commun. 2022; 607:44-48. DOI: 10.1016/j.bbrc.2022.03.121. View

Sala M, Chen C, Zhang Q, Do-Umehara H, Wu W, Misharin A . JNK2 up-regulates hypoxia-inducible factors and contributes to hypoxia-induced erythropoiesis and pulmonary hypertension. J Biol Chem. 2017; 293(1):271-284. PMC: 5766905. DOI: 10.1074/jbc.RA117.000440. View

Yamamura A, Yamamura H, Guo Q, Zimnicka A, Wan J, Ko E . Dihydropyridine Ca(2+) channel blockers increase cytosolic [Ca(2+)] by activating Ca(2+)-sensing receptors in pulmonary arterial smooth muscle cells. Circ Res. 2013; 112(4):640-50. PMC: 3642037. DOI: 10.1161/CIRCRESAHA.113.300897. View

Kuhr F, Smith K, Song M, Levitan I, Yuan J . New mechanisms of pulmonary arterial hypertension: role of Ca²⁺ signaling. Am J Physiol Heart Circ Physiol. 2012; 302(8):H1546-62. PMC: 3330808. DOI: 10.1152/ajpheart.00944.2011. View

Jin N, Hatton N, Swartz D, Xia X, Harrington M, Larsen S . Hypoxia activates jun-N-terminal kinase, extracellular signal-regulated protein kinase, and p38 kinase in pulmonary arteries. Am J Respir Cell Mol Biol. 2000; 23(5):593-601. DOI: 10.1165/ajrcmb.23.5.3921. View

Kawade A, Yamamura A, Fujiwara M, Kobayashi S, Mori S, Horii C . Comparative analysis of age in monocrotaline-induced pulmonary hypertensive rats. J Pharmacol Sci. 2021; 147(1):81-85. DOI: 10.1016/j.jphs.2021.05.012. View

Morrell N, Adnot S, Archer S, Dupuis J, Jones P, MacLean M . Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl):S20-S31. PMC: 2790324. DOI: 10.1016/j.jacc.2009.04.018. View

Decher N, Rinne S, Bedoya M, Gonzalez W, Kiper A . Molecular Pharmacology of K Potassium Channels. Cell Physiol Biochem. 2021; 55(S3):87-107. DOI: 10.33594/000000339. View

Smith K, Voiriot G, Tang H, Fraidenburg D, Song S, Yamamura H . Notch Activation of Ca(2+) Signaling in the Development of Hypoxic Pulmonary Vasoconstriction and Pulmonary Hypertension. Am J Respir Cell Mol Biol. 2015; 53(3):355-67. PMC: 4566064. DOI: 10.1165/rcmb.2014-0235OC. View

10.

Benza R, Miller D, Barst R, Badesch D, Frost A, McGoon M . An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012; 142(2):448-456. DOI: 10.1378/chest.11-1460. View

11.

Willer A, Santos-Gomes J, Adao R, Bras-Silva C, Eyries M, Perez-Vizcaino F . Physiological and pathophysiological roles of the KCNK3 potassium channel in the pulmonary circulation and the heart. J Physiol. 2023; 601(17):3717-3737. DOI: 10.1113/JP284936. View

12.

Tang H, Yamamura A, Yamamura H, Song S, Fraidenburg D, Chen J . Pathogenic role of calcium-sensing receptors in the development and progression of pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2016; 310(9):L846-59. PMC: 4867349. DOI: 10.1152/ajplung.00050.2016. View

13.

Lambert M, Boet A, Rucker-Martin C, Mendes-Ferreira P, Capuano V, Hatem S . Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. Cardiovasc Res. 2018; 114(6):880-893. DOI: 10.1093/cvr/cvy016. View

14.

Kawade A, Yamamura A, Kondo R, Suzuki Y, Yamamura H . Corosolic acid ameliorates vascular remodeling in pulmonary arterial hypertension via the downregulation of STAT3 signaling. J Pharmacol Sci. 2023; 151(2):119-127. DOI: 10.1016/j.jphs.2022.12.007. View

15.

Badesch D, Raskob G, Elliott C, Krichman A, Farber H, Frost A . Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2009; 137(2):376-87. DOI: 10.1378/chest.09-1140. View

16.

Pandit L, Lloyd E, Reynolds J, Lawrence W, Reynolds C, Wehrens X . TWIK-2 channel deficiency leads to pulmonary hypertension through a rho-kinase-mediated process. Hypertension. 2014; 64(6):1260-5. PMC: 4231005. DOI: 10.1161/HYPERTENSIONAHA.114.03406. View

17.

Yamamura A, Guo Q, Yamamura H, Zimnicka A, Pohl N, Smith K . Enhanced Ca(2+)-sensing receptor function in idiopathic pulmonary arterial hypertension. Circ Res. 2012; 111(4):469-81. PMC: 3695473. DOI: 10.1161/CIRCRESAHA.112.266361. View

18.

Enyedi P, Czirjak G . Molecular background of leak K+ currents: two-pore domain potassium channels. Physiol Rev. 2010; 90(2):559-605. DOI: 10.1152/physrev.00029.2009. View

19.

Southgate L, Machado R, Graf S, Morrell N . Molecular genetic framework underlying pulmonary arterial hypertension. Nat Rev Cardiol. 2019; 17(2):85-95. DOI: 10.1038/s41569-019-0242-x. View

20.

Ling Y, Johnson M, Kiely D, Condliffe R, Elliot C, Gibbs J . Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med. 2012; 186(8):790-6. DOI: 10.1164/rccm.201203-0383OC. View